After Kaletra setback, AbbVie joins forces with biotech, academia for experimental COVID-19 hopeful

Earlier this year, AbbVie tried and stumbled in a clinical trial using its HIV med Kaletra to help certain COVID-19 patients; now, it’s tapping a triumvirate of life science groups to develop a new antibody for the virus.